Stocktaking: Lancet Research Selection sq., May 16, 2020

Reedsiwe treatment of severe 2019 new coronary pneumonia effect is not significant
https://doi.org/10.1016/ S0140-6736 (20) 31022-9currently, there is no effective 2019 new coronary pneumonia treatment drugs, Ridsywe (Redsiewe ( GS-5734 has in vitro inhibition of Severe Acute Respiratory Syndrome (SARS-CoV-2) and better activity in animal models of MERS coronavirus, SARS-CoV-1 and SARS-CoV-2recently researchers carried out a double-blind randomized placebo-controlled study, 18 years of age and older, laboratory-confirmed 2019 new coronary pneumonia patients involved in the study, patients with symptoms of no more than 12 days, blood oxygen saturation of less than 94%, arterial oxygen levels down to 300 mmHg, radiology confirmed the presence of pneumonia symptoms, randomly received Redsive injection (day 1 200 mg)Then 2-10 days, 100 mg per day) or placeboThe main endpoint of the study was 28 days of clinical improvement237 patients participated in the study, including 158 in the Redsywe group and 79 in the placebo groupThe study found that Redcywethe treatment was not associated with clinical improvement (HR s 1.23)In patients with symptoms less than 10 days, treatment for Redcivir did not significantly improve the time of symptom relief (HR s 1.52)Sixty-six percent of patients treated with Rhaidsiwe and 64 percent of patients treated with a placebo had adverse events, and 18 were hospitalized early (12 percent) and 4 in the placebo group (5%) had adverse events2 Nivolumab treatment phase IV melanomaDOI: https://doi.org/10.1016/S0140-6736 (20) 30417-7researchers recently evaluated the efficacy of Nivolumab combined Ipilimumab or Nivolumab monotherapy for stage IV melanomathis study was a Phase II clinical study in which 167 patients aged 18-80 years with stage IV melanoma were involved, with no signs of disease after cancer or post-radiation therapy, including 56 members of the Nivolumab group, 59 in the Nivolumab group and 52 in the placebo groupIn the median follow-up of 28.4 months, there was no recurrence in the Nivolumab-Ipilimumab group, while the non-recurrent survival rate was 12.4 months in the Nivolumab group and 6.4 months in the placebo groupIn the Nivolumab-Ipilimumab group, the recurrence risk ratio was 0.23 compared to the placebo group, and the recurrence risk ratio was 0.56 in the Nivolumab group compared to the placebo group The 1-year recurrent survival rate was 75% in the Nivolumab-Ipilimumab group, 70% in 2 years, 52% in the Nivolumab group and 42% in 2 years, and 32% in the placebo group for 1 year and 14% for 2 years Treatment-related level 3-4 adverse events were reported in 71% of patients in the Nivolumab-Ipilimumab group and 27% of patients in the Nivolumab group Any level of treatment-related adverse events caused the combined group to stop treatment in 34 cases (62%) and 7 (13%) in the single drug group to stop treatment Three adverse event deaths were reported, but not treatment , Atezolizumab first-line treatment of metastatic urinary tract cancer DOI: https://doi.org/10.1016/S0140-6736 (20) 30230-0
researchers recently published the results of the IMvigor130 study, which compared atezolizumab's joint or non-joint treatment of first-form uremia disease adults with untreated topical advanced or metastatic urinary tract cancer, randomized patients with Atezolizumab combined platinum chemotherapy (group A), Atezolizumab single-drug therapy (group B), or placebo-plus platinum chemotherapy (group C) Chemotherapy regimens are given for gisitabine in combination with caporplatinum or cisplatin, 21 days for a cycle, while the Atezolizumab treatment group injects 1200mg of the drug intravenously on the first day of each cycle The main endpoints of the study were progression-free survival and total survival 1213 patients participated in the study, of which 451 in Group A (37%), 362 in Group B (30%), 400 in Group C (33%), with a median survival of 11.8 months for all patients At the time of the final analysis, the median progression lifetime in Group A was 8.2 months and group C was 6.3 months (HR s 0.82) The median total lifetime Group A was 16.0 months and Group C was 13.4 months (0.83) The median total lifetime in Group B was 15.7 months Adverse events leading to discontinuation: 156 cases in Group A (34%), 22 in Group B (6%) and 132 in Group C (34%) Group A had adverse events in 50 cases (11%), 21 in Group B (6%) and 27 in Group C (7%), leading to discontinuation of atezolizumab or placebo Source: MedSci Original